Kevin Deane
Concepts (466)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 121 | 2025 | 1167 | 18.720 |
Why?
| | Autoantibodies | 67 | 2025 | 1496 | 7.900 |
Why?
| | Anti-Citrullinated Protein Antibodies | 28 | 2025 | 115 | 6.290 |
Why?
| | Rheumatoid Factor | 40 | 2025 | 175 | 5.640 |
Why?
| | Peptides, Cyclic | 30 | 2025 | 259 | 3.480 |
Why?
| | Autoimmunity | 23 | 2025 | 908 | 3.240 |
Why?
| | Antirheumatic Agents | 12 | 2025 | 293 | 2.600 |
Why?
| | Rheumatic Diseases | 4 | 2022 | 81 | 1.730 |
Why?
| | Sputum | 5 | 2025 | 311 | 1.680 |
Why?
| | Methotrexate | 5 | 2025 | 260 | 1.550 |
Why?
| | Lung Diseases, Interstitial | 10 | 2025 | 638 | 1.240 |
Why?
| | Humans | 157 | 2025 | 137585 | 1.210 |
Why?
| | Biomarkers | 31 | 2025 | 4149 | 1.200 |
Why?
| | Immunoglobulin A | 11 | 2023 | 211 | 1.150 |
Why?
| | HIV Infections | 5 | 2023 | 2836 | 1.130 |
Why?
| | Autoimmune Diseases | 5 | 2024 | 460 | 1.110 |
Why?
| | Disease Progression | 18 | 2025 | 2757 | 1.000 |
Why?
| | Autoantigens | 8 | 2023 | 430 | 0.990 |
Why?
| | Malaria | 2 | 2025 | 63 | 0.940 |
Why?
| | Arthralgia | 3 | 2025 | 56 | 0.930 |
Why?
| | Bronchial Diseases | 3 | 2013 | 37 | 0.870 |
Why?
| | Early Medical Intervention | 2 | 2014 | 57 | 0.860 |
Why?
| | Extracellular Traps | 3 | 2021 | 53 | 0.840 |
Why?
| | Genetic Predisposition to Disease | 16 | 2023 | 2426 | 0.820 |
Why?
| | Female | 95 | 2025 | 73304 | 0.820 |
Why?
| | Inflammation | 10 | 2024 | 2837 | 0.810 |
Why?
| | Male | 82 | 2025 | 67762 | 0.810 |
Why?
| | Risk Factors | 32 | 2025 | 10388 | 0.770 |
Why?
| | Middle Aged | 71 | 2025 | 33479 | 0.770 |
Why?
| | Mucous Membrane | 2 | 2024 | 125 | 0.770 |
Why?
| | Lung Diseases | 4 | 2022 | 767 | 0.760 |
Why?
| | Rheumatology | 6 | 2021 | 118 | 0.750 |
Why?
| | Early Diagnosis | 8 | 2022 | 242 | 0.750 |
Why?
| | Mosquito Vectors | 1 | 2022 | 30 | 0.740 |
Why?
| | Insecticides | 1 | 2022 | 38 | 0.730 |
Why?
| | Lupus Erythematosus, Systemic | 4 | 2022 | 242 | 0.730 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 230 | 0.730 |
Why?
| | Case-Control Studies | 19 | 2025 | 3556 | 0.720 |
Why?
| | Joints | 4 | 2015 | 105 | 0.710 |
Why?
| | Precision Medicine | 3 | 2020 | 429 | 0.710 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 15 | 0.690 |
Why?
| | Epitopes | 8 | 2023 | 479 | 0.670 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 214 | 0.620 |
Why?
| | Citrullination | 2 | 2020 | 13 | 0.620 |
Why?
| | Adult | 56 | 2025 | 37929 | 0.620 |
Why?
| | Histones | 4 | 2023 | 636 | 0.610 |
Why?
| | Lung | 7 | 2020 | 4060 | 0.600 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 852 | 0.600 |
Why?
| | Aged | 42 | 2025 | 23961 | 0.580 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 213 | 0.570 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 89 | 0.550 |
Why?
| | Immunoglobulin G | 11 | 2023 | 893 | 0.540 |
Why?
| | Transgender Persons | 1 | 2020 | 186 | 0.540 |
Why?
| | Pedigree | 2 | 2020 | 514 | 0.530 |
Why?
| | Synovitis | 2 | 2023 | 27 | 0.520 |
Why?
| | Citrulline | 2 | 2016 | 45 | 0.520 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2015 | 59 | 0.510 |
Why?
| | Qualitative Research | 5 | 2024 | 1386 | 0.510 |
Why?
| | Human Migration | 1 | 2016 | 22 | 0.500 |
Why?
| | Transients and Migrants | 1 | 2016 | 24 | 0.500 |
Why?
| | Rituximab | 3 | 2025 | 176 | 0.500 |
Why?
| | Synovial Membrane | 4 | 2025 | 117 | 0.490 |
Why?
| | Arthritis | 2 | 2016 | 95 | 0.490 |
Why?
| | Immunoglobulin M | 7 | 2023 | 289 | 0.470 |
Why?
| | Prospective Studies | 21 | 2025 | 7604 | 0.460 |
Why?
| | Th17 Cells | 3 | 2025 | 108 | 0.450 |
Why?
| | Abatacept | 2 | 2025 | 53 | 0.450 |
Why?
| | Cytokines | 10 | 2023 | 2085 | 0.430 |
Why?
| | Sexual Behavior | 2 | 2016 | 485 | 0.430 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 806 | 0.430 |
Why?
| | Family | 7 | 2021 | 671 | 0.430 |
Why?
| | Antipsychotic Agents | 1 | 2016 | 194 | 0.430 |
Why?
| | Pneumonia | 1 | 2020 | 639 | 0.430 |
Why?
| | Psychotic Disorders | 1 | 2016 | 170 | 0.420 |
Why?
| | Endothelium, Vascular | 4 | 2013 | 927 | 0.410 |
Why?
| | Risk-Taking | 1 | 2016 | 348 | 0.410 |
Why?
| | Chemokines | 2 | 2012 | 228 | 0.410 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2013 | 46 | 0.400 |
Why?
| | Hydroxychloroquine | 2 | 2025 | 58 | 0.390 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 220 | 0.390 |
Why?
| | Tanzania | 3 | 2021 | 58 | 0.390 |
Why?
| | Hazardous Substances | 1 | 2012 | 18 | 0.380 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 117 | 0.380 |
Why?
| | Risk Assessment | 8 | 2025 | 3457 | 0.360 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.360 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 140 | 0.350 |
Why?
| | Gene-Environment Interaction | 1 | 2012 | 192 | 0.340 |
Why?
| | B-Lymphocytes | 3 | 2025 | 847 | 0.340 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 77 | 0.340 |
Why?
| | Smoking | 9 | 2024 | 1627 | 0.340 |
Why?
| | Social Stigma | 2 | 2023 | 137 | 0.330 |
Why?
| | Emigration and Immigration | 1 | 2010 | 46 | 0.330 |
Why?
| | Mass Screening | 3 | 2020 | 1287 | 0.330 |
Why?
| | Protein Processing, Post-Translational | 1 | 2013 | 465 | 0.330 |
Why?
| | Mucin-5B | 3 | 2025 | 224 | 0.330 |
Why?
| | Malondialdehyde | 2 | 2020 | 29 | 0.330 |
Why?
| | Acetaldehyde | 2 | 2020 | 17 | 0.330 |
Why?
| | Health Fairs | 1 | 2009 | 9 | 0.330 |
Why?
| | Postmenopause | 7 | 2023 | 366 | 0.320 |
Why?
| | Antibodies, Antinuclear | 5 | 2023 | 71 | 0.320 |
Why?
| | Research Design | 3 | 2024 | 1139 | 0.320 |
Why?
| | Glucocorticoids | 3 | 2021 | 594 | 0.300 |
Why?
| | Antibodies, Bacterial | 3 | 2023 | 146 | 0.290 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2025 | 1242 | 0.290 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1050 | 0.290 |
Why?
| | Incidence | 9 | 2021 | 2804 | 0.280 |
Why?
| | Focus Groups | 2 | 2024 | 522 | 0.280 |
Why?
| | Health Behavior | 3 | 2018 | 762 | 0.270 |
Why?
| | B-Cell Activating Factor | 2 | 2024 | 21 | 0.270 |
Why?
| | Chlamydia trachomatis | 2 | 2025 | 49 | 0.250 |
Why?
| | Antibody Formation | 4 | 2023 | 298 | 0.250 |
Why?
| | Immunophenotyping | 2 | 2025 | 318 | 0.250 |
Why?
| | Cross-Sectional Studies | 9 | 2023 | 5472 | 0.250 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 25 | 0.240 |
Why?
| | Chlamydia Infections | 2 | 2025 | 75 | 0.240 |
Why?
| | Developing Countries | 2 | 2025 | 307 | 0.240 |
Why?
| | Qa-SNARE Proteins | 1 | 2025 | 20 | 0.240 |
Why?
| | Vasculitis | 1 | 2005 | 66 | 0.230 |
Why?
| | HLA-B27 Antigen | 1 | 2024 | 16 | 0.230 |
Why?
| | Arthritis, Psoriatic | 1 | 2024 | 21 | 0.230 |
Why?
| | Longitudinal Studies | 5 | 2025 | 2844 | 0.220 |
Why?
| | Complement Factor H | 1 | 2025 | 80 | 0.220 |
Why?
| | Complement Activation | 2 | 2025 | 415 | 0.220 |
Why?
| | Spondylarthritis | 1 | 2024 | 50 | 0.210 |
Why?
| | Animals | 11 | 2025 | 36940 | 0.210 |
Why?
| | Polysaccharides | 2 | 2017 | 79 | 0.210 |
Why?
| | Likelihood Functions | 1 | 2024 | 144 | 0.210 |
Why?
| | Clinical Decision-Making | 2 | 2024 | 322 | 0.210 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 73 | 0.210 |
Why?
| | Risk | 3 | 2016 | 912 | 0.210 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 137 | 0.210 |
Why?
| | London | 1 | 2023 | 47 | 0.200 |
Why?
| | Africa South of the Sahara | 1 | 2023 | 48 | 0.200 |
Why?
| | Estrogens | 3 | 2017 | 367 | 0.200 |
Why?
| | HLA-DR Antigens | 1 | 2024 | 228 | 0.200 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.200 |
Why?
| | Time Factors | 6 | 2019 | 6828 | 0.200 |
Why?
| | Down-Regulation | 1 | 2025 | 657 | 0.200 |
Why?
| | Autophagy | 1 | 2025 | 284 | 0.200 |
Why?
| | Patient Education as Topic | 3 | 2018 | 766 | 0.190 |
Why?
| | Periodontal Diseases | 1 | 2023 | 61 | 0.190 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.190 |
Why?
| | Mouth Mucosa | 3 | 2023 | 92 | 0.190 |
Why?
| | Trichloroethylene | 1 | 2022 | 8 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 480 | 0.190 |
Why?
| | Insecticide-Treated Bednets | 1 | 2022 | 6 | 0.190 |
Why?
| | Gender Identity | 1 | 2023 | 124 | 0.190 |
Why?
| | Biological Products | 2 | 2022 | 216 | 0.180 |
Why?
| | Homosexuality, Male | 1 | 2023 | 184 | 0.180 |
Why?
| | Policy | 1 | 2023 | 150 | 0.180 |
Why?
| | Blood Platelets | 1 | 2025 | 408 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 3 | 2024 | 558 | 0.180 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 900 | 0.180 |
Why?
| | Pulmonary Fibrosis | 1 | 2025 | 402 | 0.180 |
Why?
| | Prevalence | 4 | 2022 | 2734 | 0.180 |
Why?
| | Young Adult | 9 | 2021 | 13209 | 0.180 |
Why?
| | Women's Health | 5 | 2017 | 372 | 0.180 |
Why?
| | Sex Factors | 5 | 2020 | 2071 | 0.180 |
Why?
| | Organ Specificity | 2 | 2019 | 305 | 0.180 |
Why?
| | Social Determinants of Health | 1 | 2025 | 267 | 0.180 |
Why?
| | Hemorrhage | 1 | 2005 | 722 | 0.170 |
Why?
| | Lymphocyte Activation | 1 | 2025 | 1142 | 0.170 |
Why?
| | Neutrophil Activation | 1 | 2021 | 80 | 0.170 |
Why?
| | Housing | 1 | 2022 | 146 | 0.170 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 99 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 98 | 0.170 |
Why?
| | Sarcoidosis | 1 | 2022 | 159 | 0.170 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.170 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.170 |
Why?
| | Museums | 1 | 2000 | 11 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 192 | 0.160 |
Why?
| | Intestines | 2 | 2021 | 357 | 0.160 |
Why?
| | Severity of Illness Index | 8 | 2022 | 2828 | 0.160 |
Why?
| | Complement System Proteins | 2 | 2022 | 327 | 0.160 |
Why?
| | Muramidase | 1 | 2020 | 78 | 0.160 |
Why?
| | Sjogren's Syndrome | 1 | 2020 | 54 | 0.160 |
Why?
| | Public-Private Sector Partnerships | 1 | 2020 | 43 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 185 | 0.160 |
Why?
| | Art Therapy | 1 | 2000 | 20 | 0.160 |
Why?
| | Bacteriophages | 1 | 2021 | 98 | 0.160 |
Why?
| | United Kingdom | 1 | 2020 | 318 | 0.160 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 85 | 0.160 |
Why?
| | Retrospective Studies | 5 | 2024 | 15657 | 0.160 |
Why?
| | C-Reactive Protein | 6 | 2025 | 410 | 0.160 |
Why?
| | Attitude | 1 | 2021 | 259 | 0.160 |
Why?
| | Nuclear Family | 1 | 2019 | 54 | 0.150 |
Why?
| | Age Factors | 7 | 2020 | 3295 | 0.150 |
Why?
| | Inflammation Mediators | 2 | 2020 | 513 | 0.150 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 46 | 0.150 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 36 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1091 | 0.150 |
Why?
| | Gene Expression | 2 | 2022 | 1502 | 0.150 |
Why?
| | Mitochondria | 2 | 2025 | 948 | 0.150 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 147 | 0.150 |
Why?
| | Dexamethasone | 1 | 2020 | 368 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 455 | 0.140 |
Why?
| | Occupational Exposure | 1 | 2022 | 341 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1111 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 563 | 0.140 |
Why?
| | HLA-DR4 Antigen | 3 | 2007 | 78 | 0.140 |
Why?
| | Cohort Studies | 10 | 2022 | 5742 | 0.140 |
Why?
| | Cellular Senescence | 1 | 2019 | 189 | 0.140 |
Why?
| | Military Personnel | 2 | 2021 | 544 | 0.140 |
Why?
| | Vascular Stiffness | 2 | 2013 | 494 | 0.140 |
Why?
| | Metabolome | 1 | 2020 | 350 | 0.130 |
Why?
| | Remission Induction | 2 | 2021 | 288 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 33 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.130 |
Why?
| | Decision Making | 1 | 2024 | 900 | 0.130 |
Why?
| | Glycosylation | 1 | 2017 | 151 | 0.130 |
Why?
| | Seroepidemiologic Studies | 3 | 2014 | 165 | 0.130 |
Why?
| | Coronary Disease | 2 | 2017 | 385 | 0.130 |
Why?
| | Hydrolases | 2 | 2021 | 48 | 0.130 |
Why?
| | Sex Work | 1 | 2016 | 22 | 0.130 |
Why?
| | Adiponectin | 1 | 2018 | 244 | 0.130 |
Why?
| | Plasma Cells | 1 | 2016 | 71 | 0.130 |
Why?
| | United States | 8 | 2022 | 14841 | 0.130 |
Why?
| | Estradiol | 3 | 2017 | 521 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 240 | 0.120 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1946 | 0.120 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 600 | 0.120 |
Why?
| | Diagnosis, Differential | 3 | 2013 | 1483 | 0.120 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2019 | 657 | 0.120 |
Why?
| | Mothers | 1 | 2021 | 754 | 0.120 |
Why?
| | Neutrophils | 1 | 2021 | 1238 | 0.120 |
Why?
| | Peptides | 1 | 2021 | 985 | 0.120 |
Why?
| | Tertiary Prevention | 1 | 2014 | 3 | 0.110 |
Why?
| | Diet | 2 | 2020 | 1278 | 0.110 |
Why?
| | Vasodilation | 3 | 2013 | 499 | 0.110 |
Why?
| | Adaptation, Psychological | 1 | 2000 | 655 | 0.110 |
Why?
| | Cardiovascular Diseases | 3 | 2017 | 2111 | 0.110 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1066 | 0.110 |
Why?
| | Alcohol Drinking | 1 | 2020 | 828 | 0.110 |
Why?
| | Neoplasms | 2 | 2017 | 2671 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 233 | 0.100 |
Why?
| | Respiratory Mucosa | 1 | 2016 | 321 | 0.100 |
Why?
| | Socioeconomic Factors | 3 | 2025 | 1289 | 0.100 |
Why?
| | Bacteroidaceae Infections | 1 | 2012 | 7 | 0.100 |
Why?
| | Blood Pressure | 2 | 2017 | 1786 | 0.100 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 164 | 0.100 |
Why?
| | Porphyromonas gingivalis | 1 | 2012 | 23 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 196 | 0.100 |
Why?
| | Family Health | 2 | 2013 | 196 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 951 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 4 | 2025 | 2691 | 0.100 |
Why?
| | Vitamin D | 2 | 2022 | 397 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2014 | 363 | 0.100 |
Why?
| | Periodontitis | 1 | 2012 | 53 | 0.100 |
Why?
| | Communicable Disease Control | 2 | 2024 | 82 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1100 | 0.090 |
Why?
| | Health | 1 | 2012 | 84 | 0.090 |
Why?
| | Arthrography | 1 | 2011 | 17 | 0.090 |
Why?
| | Telomere Shortening | 2 | 2024 | 20 | 0.090 |
Why?
| | Population Surveillance | 1 | 2015 | 482 | 0.090 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 116 | 0.090 |
Why?
| | Delayed Diagnosis | 1 | 2012 | 91 | 0.090 |
Why?
| | RNA, Messenger | 3 | 2025 | 2833 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2031 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1266 | 0.090 |
Why?
| | Disease Susceptibility | 3 | 2021 | 347 | 0.090 |
Why?
| | Asthma | 1 | 2024 | 2295 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2253 | 0.090 |
Why?
| | Labor, Induced | 1 | 2011 | 33 | 0.090 |
Why?
| | Logistic Models | 5 | 2020 | 2074 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 86 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5131 | 0.090 |
Why?
| | Time-to-Treatment | 1 | 2012 | 205 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2020 | 3284 | 0.080 |
Why?
| | Phenotype | 4 | 2023 | 3196 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2011 | 247 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 132 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1329 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2012 | 331 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 431 | 0.080 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 318 | 0.080 |
Why?
| | Menopause | 1 | 2012 | 320 | 0.080 |
Why?
| | Air Pollution | 1 | 2013 | 316 | 0.080 |
Why?
| | Colorado | 3 | 2020 | 4565 | 0.080 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 98 | 0.080 |
Why?
| | Aging | 1 | 2019 | 1864 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2021 | 10811 | 0.070 |
Why?
| | Interleukin-6 | 3 | 2021 | 778 | 0.070 |
Why?
| | Odds Ratio | 3 | 2018 | 1070 | 0.070 |
Why?
| | Aspirin | 1 | 2011 | 387 | 0.070 |
Why?
| | Alleles | 3 | 2019 | 891 | 0.070 |
Why?
| | Colposcopy | 1 | 2007 | 18 | 0.070 |
Why?
| | Obesity | 1 | 2020 | 2992 | 0.070 |
Why?
| | Disease Outbreaks | 1 | 2010 | 395 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 565 | 0.070 |
Why?
| | Brachial Artery | 3 | 2013 | 205 | 0.070 |
Why?
| | Societies, Medical | 2 | 2021 | 820 | 0.070 |
Why?
| | Stroke | 1 | 2015 | 1120 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 33 | 0.060 |
Why?
| | Mice | 4 | 2025 | 17787 | 0.060 |
Why?
| | Capillaries | 1 | 2005 | 108 | 0.060 |
Why?
| | Environment | 2 | 2019 | 358 | 0.060 |
Why?
| | Switzerland | 1 | 2025 | 37 | 0.060 |
Why?
| | Premenopause | 2 | 2017 | 131 | 0.060 |
Why?
| | Radiography, Thoracic | 1 | 2005 | 167 | 0.060 |
Why?
| | Healthy Volunteers | 2 | 2017 | 199 | 0.060 |
Why?
| | Bronchoscopy | 1 | 2005 | 223 | 0.060 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 56 | 0.060 |
Why?
| | Receptors, CXCR5 | 1 | 2024 | 21 | 0.060 |
Why?
| | Pregnancy | 2 | 2021 | 6763 | 0.050 |
Why?
| | Uganda | 1 | 2024 | 77 | 0.050 |
Why?
| | Quarantine | 1 | 2024 | 30 | 0.050 |
Why?
| | Immunity, Mucosal | 2 | 2014 | 97 | 0.050 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2023 | 26 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2024 | 7635 | 0.050 |
Why?
| | Interleukin-2 | 2 | 2016 | 455 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 405 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 410 | 0.050 |
Why?
| | Vimentin | 1 | 2023 | 52 | 0.050 |
Why?
| | Employment | 1 | 2024 | 178 | 0.050 |
Why?
| | Biopsy | 1 | 2005 | 1129 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1509 | 0.050 |
Why?
| | Immunoglobulins | 2 | 2015 | 171 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2022 | 332 | 0.050 |
Why?
| | Poverty | 1 | 2025 | 521 | 0.040 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 43 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 5778 | 0.040 |
Why?
| | Body Mass Index | 2 | 2020 | 2389 | 0.040 |
Why?
| | Janus Kinase Inhibitors | 1 | 2021 | 26 | 0.040 |
Why?
| | Carotid Arteries | 2 | 2013 | 206 | 0.040 |
Why?
| | Putrescine | 1 | 2020 | 2 | 0.040 |
Why?
| | Butyric Acid | 1 | 2020 | 7 | 0.040 |
Why?
| | Xenobiotics | 1 | 2021 | 32 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 166 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 344 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 185 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 280 | 0.040 |
Why?
| | Spermidine | 1 | 2020 | 19 | 0.040 |
Why?
| | Urban Population | 1 | 2024 | 479 | 0.040 |
Why?
| | Caprylates | 1 | 2020 | 25 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 890 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 84 | 0.040 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 4 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 77 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2024 | 786 | 0.040 |
Why?
| | Chemokine CXCL13 | 1 | 2020 | 8 | 0.040 |
Why?
| | Europe | 1 | 2021 | 414 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 68 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1325 | 0.040 |
Why?
| | Microbiota | 2 | 2021 | 762 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 27 | 0.040 |
Why?
| | Carnitine | 1 | 2020 | 84 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1178 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 67 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 656 | 0.040 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 39 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 268 | 0.040 |
Why?
| | Anxiety | 1 | 2007 | 1035 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 160 | 0.040 |
Why?
| | Child Health | 1 | 2021 | 154 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 390 | 0.040 |
Why?
| | Interleukin-1alpha | 1 | 2020 | 58 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 189 | 0.040 |
Why?
| | Interinstitutional Relations | 1 | 2000 | 53 | 0.040 |
Why?
| | Ontario | 1 | 2000 | 148 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4295 | 0.040 |
Why?
| | Rural Population | 1 | 2024 | 563 | 0.040 |
Why?
| | Baltimore | 1 | 2019 | 60 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 198 | 0.040 |
Why?
| | Tryptophan | 1 | 2020 | 183 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 220 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 372 | 0.040 |
Why?
| | Genotype | 2 | 2018 | 1916 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4030 | 0.040 |
Why?
| | Interferons | 1 | 2020 | 202 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 718 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2018 | 17 | 0.040 |
Why?
| | Dysbiosis | 1 | 2020 | 181 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 250 | 0.040 |
Why?
| | Forecasting | 1 | 2020 | 389 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2025 | 3015 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 683 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 622 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 138 | 0.040 |
Why?
| | Nurses | 1 | 2020 | 180 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 521 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 625 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 305 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 460 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 7 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 2189 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 500 | 0.030 |
Why?
| | Amino Acids | 1 | 2021 | 497 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1276 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 20 | 0.030 |
Why?
| | Raloxifene Hydrochloride | 1 | 2017 | 15 | 0.030 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2017 | 29 | 0.030 |
Why?
| | Leuprolide | 1 | 2017 | 20 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 904 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2021 | 421 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 4 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 15 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 54 | 0.030 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2017 | 49 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 858 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 93 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 669 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 771 | 0.030 |
Why?
| | Health Education | 1 | 2018 | 341 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2000 | 660 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1430 | 0.030 |
Why?
| | Androgens | 1 | 2017 | 187 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2016 | 128 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2017 | 212 | 0.030 |
Why?
| | Adolescent | 4 | 2021 | 21513 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1996 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1639 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 329 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 971 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2015 | 106 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1250 | 0.030 |
Why?
| | Etanercept | 1 | 2013 | 57 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2014 | 112 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 812 | 0.030 |
Why?
| | Motivation | 1 | 2018 | 570 | 0.030 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 12 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 409 | 0.030 |
Why?
| | Geographic Information Systems | 1 | 2013 | 45 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3566 | 0.020 |
Why?
| | Oral Health | 1 | 2014 | 124 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 539 | 0.020 |
Why?
| | Interleukin-9 | 1 | 2012 | 12 | 0.020 |
Why?
| | Communication | 1 | 2018 | 879 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 738 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1622 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 303 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 152 | 0.020 |
Why?
| | Life Style | 1 | 2014 | 490 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2014 | 236 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 561 | 0.020 |
Why?
| | Connective Tissue Diseases | 1 | 2012 | 84 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1062 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3958 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 700 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 315 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 350 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 370 | 0.020 |
Why?
| | Internet | 1 | 2014 | 655 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2057 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 558 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 684 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 789 | 0.020 |
Why?
| | Child | 3 | 2021 | 21935 | 0.020 |
Why?
| | Self Report | 1 | 2013 | 827 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 759 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2607 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 21 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 126 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1704 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1040 | 0.020 |
Why?
| | Veterans | 1 | 2018 | 1476 | 0.020 |
Why?
| | Hypertension | 1 | 2015 | 1295 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 257 | 0.010 |
Why?
| | Tobacco Smoke Pollution | 1 | 2007 | 261 | 0.010 |
Why?
| | Siblings | 1 | 2005 | 228 | 0.010 |
Why?
| | Pain | 1 | 2007 | 756 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1477 | 0.010 |
Why?
| | Arthritis, Infectious | 1 | 1994 | 69 | 0.010 |
Why?
| | Child, Preschool | 1 | 2007 | 11074 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2006 | 3715 | 0.000 |
Why?
|
|
Deane's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|